-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-10-16
Values as of: 2019-10-16
The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, creates short positions by investing at least 80% of its assets in: swap agreements; futures contracts; options; reverse repurchase agreements; exchange-traded funds ("ETFs"); and other financial instruments that, in combination, provide inverse leveraged and unleveraged exposure to the S&P Biotechnology Select Industry Index. The index includes domestic companies from the biotechnology industry. The fund is non-diversified.
Company Website : http://www.direxioninvestments.com/
Currency: USD
Country : USA
Inception Date: 28/05/2015
Primary Benchmark: S&P Biotechnology Select Industry TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 1.55%
Management Expense Ratio: 1.00 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| SOJE | SOJE | 0.00 % |
+0.01 (+0.05%) |
USD 65.72B |
| JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.02 (-0.04%) |
USD 32.78B |
| LCR | Leuthold Core ETF | 0.00 % |
-0.06 (-0.17%) |
USD 32.52B |
| DTB | DTB | 0.00 % |
+0.02 (+0.11%) |
USD 26.58B |
| DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.12 (-0.40%) |
USD 26.11B |
| JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
N/A |
USD 22.47B |
| SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
| TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.33 (-1.05%) |
USD 16.23B |
| DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.27 (+0.70%) |
USD 10.15B |
| AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+1.11 (+1.28%) |
USD 10.05B |
N/A
| Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -46.59% | 1% | F | 3% | F | ||
| Dividend Return | 0.47% | 9% | A- | 6% | D- | ||
| Total Return | -46.11% | 1% | F | 3% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -20.63% | 8% | B- | 18% | F | ||
| Dividend Return | 1.37% | 35% | F | 25% | F | ||
| Total Return | -19.26% | 7% | C- | 17% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | F | ||
| Total Return | N/A | N/A | N/A | N/A | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -42.15% | N/A | F | N/A | F | ||
| Dividend Return | -41.85% | N/A | F | N/A | F | ||
| Total Return | 0.29% | 12% | F | 8% | B- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 30.92% | 7% | C- | 17% | F | ||
| Risk Adjusted Return | -135.37% | 1% | F | 1% | F | ||
| Market Capitalization | 0.10B | 48% | F | 21% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
